Fusion Proteins, bcr-abl

"Fusion Proteins, bcr-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.

Descriptor ID	D016044
MeSH Number(s)	D08.811.913.696.620.682.725.500.500 D12.776.602.500.500.100 D12.776.624.664.500.100 D12.776.624.664.700.171.500
Concept/Terms	Fusion Proteins, bcr-abl Fusion Proteins, bcr-abl Fusion Proteins, bcr abl bcr-abl Fusion Proteins bcr abl Fusion Proteins Bcr-Abl Tyrosine Kinase Bcr Abl Tyrosine Kinase Kinase, Bcr-Abl Tyrosine Tyrosine Kinase, Bcr-Abl Oncogene Protein p190(bcr-abl) Oncogene Protein p190(bcr-abl) p190(bcr-abl) Fusion Proteins Oncogene Protein p230(bcr-abl) Oncogene Protein p230(bcr-abl) p230(bcr-abl) Fusion Proteins Oncogene Protein p185(bcr-abl) Oncogene Protein p185(bcr-abl) p185(bcr-abl) Fusion Proteins Oncogene Protein p210(bcr-abl) Oncogene Protein p210(bcr-abl) p210(bcr-abl) Fusion Proteins

Below are MeSH descriptors whose meaning is more general than "Fusion Proteins, bcr-abl".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Proto-Oncogene Proteins c-abl [D08.811.913.696.620.682.725.500]
Fusion Proteins, bcr-abl [D08.811.913.696.620.682.725.500.500]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Mutant Proteins [D12.776.602]
Mutant Chimeric Proteins [D12.776.602.500]
Oncogene Proteins, Fusion [D12.776.602.500.500]
Fusion Proteins, bcr-abl [D12.776.602.500.500.100]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Oncogene Proteins, Fusion [D12.776.624.664.500]
Fusion Proteins, bcr-abl [D12.776.624.664.500.100]
Proto-Oncogene Proteins [D12.776.624.664.700]
Proto-Oncogene Proteins c-bcr [D12.776.624.664.700.171]
Fusion Proteins, bcr-abl [D12.776.624.664.700.171.500]

Below are MeSH descriptors whose meaning is related to "Fusion Proteins, bcr-abl".

Below are MeSH descriptors whose meaning is more specific than "Fusion Proteins, bcr-abl".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fusion Proteins, bcr-abl" by people in this website by year, and whether "Fusion Proteins, bcr-abl" was a major or minor topic of these publications.

Bar chart showing 55 publications over 24 distinct years, with a maximum of 5 publications in 1998

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	4	0	4
1997	3	0	3
1998	5	0	5
1999	0	1	1
2000	2	2	4
2001	1	1	2
2002	1	2	3
2003	1	1	2
2004	1	0	1
2005	2	0	2
2006	4	0	4
2007	1	2	3
2008	3	1	4
2009	0	2	2
2010	1	0	1
2011	2	1	3
2012	1	0	1
2013	1	0	1
2014	1	1	2
2016	0	1	1
2017	1	0	1
2018	2	1	3
2021	0	1	1
2024	0	1	1

Below are the most recent publications written about "Fusion Proteins, bcr-abl" by people in Profiles.

Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 02; 22(1):43-69.

View in: PubMed
Porazzi P, De Dominici M, Salvino J, Calabretta B. Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia. Genes (Basel). 2021 08 29; 12(9).

View in: PubMed
Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, Peterson LF, Porcu P, Nevalainen MT, Calabretta B. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. Cancer Res. 2018 10 15; 78(20):5793-5807.

View in: PubMed
Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Polakova KM. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica. 2018 12; 103(12):2016-2025.

View in: PubMed
Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O'Prey J, Hair A, Melo JV, Chan E, Ryan KM, Maguer-Satta V, Druker BJ, Clark RE, Mitra S, Herzyk P, Nicolini FE, Salomoni P, Shanks E, Calabretta B, Holyoake TL, Helgason GV. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. J Natl Cancer Inst. 2018 05 01; 110(5):467-478.

View in: PubMed
Perrotti D, Silvestri G, Stramucci L, Yu J, Trotta R. Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay. Curr Drug Targets. 2017; 18(4):377-388.

View in: PubMed
Riva B, De Dominici M, Gnemmi I, Mariani SA, Minassi A, Minieri V, Salomoni P, Canonico PL, Genazzani AA, Calabretta B, Condorelli F. Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of ?-catenin and mTORC1/2. Oncotarget. 2016 Dec 06; 7(49):81555-81570.

View in: PubMed
Frederick L, Beardell F, Viswanatha DS. Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm. Hum Pathol. 2014 Aug; 45(8):1784-9.

View in: PubMed
Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2092-103.

View in: PubMed
Singh H, Shelat AA, Singh A, Boulos N, Williams RT, Guy RK. A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia. J Biomol Screen. 2014 Jan; 19(1):158-67.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement